^
Association details:
| Biomarker: | BCL2 overexpression |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Overcoming the acquired resistance to gefitinib in lung cancer brain metastasis in vitro and in vivo
Published date:
08/28/2021
Excerpt:
AZD9291 was also shown to overcome acquired resistance to gefitinib in PC-9-Br in MTT assays (0.23 ± 0.031 µM at 48 h and 0.03 ± 0.008 µM at 72 h)....In conclusion, our study demonstrated gefitinib + ABT263/ABT199, afatinib, and AZD9291 have clinical potential to treat LCBM.
DOI:
10.1007/s00204-021-03147-4
